SAN DIEGO–(BUSINESS WIRE)–Crown Bioscience, a world contract analysis group (CRO) and JSR Life Sciences firm, introduced at the moment that it has accomplished its acquisition of the IndivuServ enterprise unit of Indivumed GmbH on March 31, 2023. With this transaction, the brand new entity, now referred to as Indivumed Companies GmbH, turns into a completely owned subsidiary of Crown Bioscience and consists of all related laboratory operations in Hamburg, Germany and Frederick, MD, US, and provides 120 workers to the Firm’s world headcount.
The acquisition of Indivumed Companies brings a spread of synergistic service platforms to Crown Bioscience, from enhanced immunohistochemistry to spatial transcriptomics, complementing the corporate’s already established capabilities supporting biomarker discovery. The deal additionally consists of an industry-leading biobank of scientific specimens distinctive in high quality and related scientific historical past, which has been expertly curated and characterised, and which at present totals nearly a million affected person samples. As well as, as a part of the acquisition, Crown Bioscience features entry to an intensive scientific community of greater than 60 entities in america, Europe, and Asia which gives direct and managed entry to related surgical biospecimens and blood samples.
Armin Spura, PhD, CEO of Crown Bioscience, said: “I’m thrilled to welcome the extremely skilled Indivumed Companies crew to Crown Bioscience. With this acquisition, we as soon as once more spend money on new capabilities to position Crown Bioscience as the popular resolution supplier to assist our companions of their early-stage drug improvement efforts.”
By buying Indivumed Companies’ capabilities, Crown Bioscience strikes nearer to the affected person, with the flexibility to supply (for each potential and retrospective collections) and analyze clinically related affected person supplies. This evaluation consists of multi-omics lab amenities on the East Coast of the US and mainland Europe. The distinctive high quality of the Indivumed Companies community and biobank, using proprietary SOPs, will even present the muse for the following era of progress in Crown Bioscience’s present platforms, guaranteeing consumer entry to the newest clinically related translational fashions throughout their ex vivo affected person tissue (EVPT), tumor organoid, and patient-derived xenograft (PDX) mannequin collections.
Michael Prosser, CBO of Crown Bioscience, added: “The completion of this acquisition demonstrates our dedication to integrating distinctive capabilities and industry-leading high quality into all areas of our enterprise. We’ll proceed to create options that meet the wants of our shoppers, empowering the {industry} to additional speed up and de-risk drug discovery and improvement.”
Indivumed Companies will initially function as a completely owned subsidiary of Crown Bioscience, sustaining operations in Germany and the US, and rising the scientific community. Monetary particulars of the transaction aren’t being disclosed.
To search out out extra, go to: www.indivumedservices.com.
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences firm, is a world CRO that gives preclinical and translational platforms to assist our prospects advance their analysis and improvement in oncology, immuno-oncology, and immune-mediated inflammatory illnesses. We’re the unique preclinical CRO to supply tumor organoid providers with the well-established Hubrecht Organoid Know-how. As well as, we have now developed the most important commercially accessible PDX assortment on this planet. We deal with serving to our prospects develop novel therapies to maximise the probabilities that sufferers obtain the fitting remedy on the proper time. Based in 2006, Crown Bioscience has 14 amenities throughout america, Europe, and Asia.
For extra data or to get in contact, please go to www.crownbio.com
Contacts
Media Inquiries:
Crown Bioscience
Louise Stenson
[email protected]
Copyright © acrofan/Enterprise Wire All Proper Reserved